Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company with a market capitalization of $11.8 million, announced today that its subsidiary, Merveille.ai, has completed the payment of all prescribed fees for a significant international patent application. The application, numbered PCT/US2025/022598, pertains to the treatment and prevention of hair loss and was confirmed by the U.S. Patent and Trademark Office, acting as the Receiving Office under the Patent Cooperation Treaty (PCT). According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, though it currently operates at a loss.
This development, dated May 2, 2025, supports Merveille.ai’s strategy to protect its intellectual property as it advances therapeutic innovation. The patent application holds a priority date of April 5, 2024, indicating the initial filing date for the patent rights.
Hoth Therapeutics, headquartered in New York, is incorporated in Nevada and is known for its work in pharmaceutical preparations. The completion of this payment step is a procedural milestone in the patent application process, which is a critical component of the company’s broader efforts to secure its intellectual property assets globally.
The company’s shares are listed on the Nasdaq Stock Market under the trading symbol HOTH. As per the SEC filing, Hoth Therapeutics is not classified as an emerging growth company and, as such, does not utilize the extended transition period for complying with new or revised financial accounting standards.
The CEO of Hoth Therapeutics, Robb Knie, signed the SEC filing, affirming the company’s compliance with the requirements of the Securities Exchange Act of 1934. This announcement is based on the information provided in the company’s recent SEC filing.
In other recent news, Hoth Therapeutics, Inc. announced positive interim results from its Phase 2a clinical trial for HT-001, aimed at treating pruritus associated with skin toxicities from EGFR inhibitors. Patients reported a 50% reduction in pruritus severity, with significant symptom relief observed within the first week of treatment. Additionally, the company revealed promising preclinical results for HT-ALZ, an Alzheimer’s drug candidate that showed cognitive improvement and reduced neuroinflammation in disease models. Hoth Therapeutics also secured a new patent in Japan for RNA cancer therapy targeting the KIT gene, enhancing its position in the RNA therapeutics field. This patent grants the company exclusive rights to develop antisense oligonucleotide-based therapies targeting the KIT gene, which is linked to aggressive cancers. Furthermore, Hoth reported progress in its preclinical studies of HT-KIT for gastrointestinal stromal tumors, demonstrating significant reductions in tumor growth and KIT protein expression. The company has also filed amended claims with the U.S. Patent Office to bolster intellectual property protection for HT-KIT. These developments are part of Hoth’s ongoing efforts to advance its pipeline of innovative therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.